title: Does tocilizumab indeed reduce the frequency of Th17 cells? Comment on the article by Thiolat et al.
authors.affiliation: INSERM U1098, Besançon, France, Université de Bourgogne Franche-Comté UMR1098, and CHU de Dijon, Dijon, France.
authors.forename: Maxime
authors.initials: M
authors.lastname: Samson
authors.forename: Sylvain
authors.initials: S
authors.lastname: Audia
authors.forename: Paul
authors.initials: P
authors.lastname: Ornetti
authors.forename: Jean-Francis
authors.initials: JF
authors.lastname: Maillefert
authors.forename: Nona
authors.initials: N
authors.lastname: Janikashvili
authors.forename: Bernard
authors.initials: B
authors.lastname: Bonnotte
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000378:metabolism*; D001081:Apyrase / Q000378:metabolism*; D001169:Arthritis, Experimental / Q000473:pathology*; D001172:Arthritis, Rheumatoid / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors*; D050378:T-Lymphocytes, Regulatory / Q000378:metabolism* / Q000473:pathology*
chemical_list: D015703:Antigens, CD; D019947:Receptors, Interleukin-6; D001081:Apyrase